<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02007005</url>
  </required_header>
  <id_info>
    <org_study_id>AB01</org_study_id>
    <nct_id>NCT02007005</nct_id>
  </id_info>
  <brief_title>Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer</brief_title>
  <official_title>Dose-Escalation-Study With abnobaVISCUM速 Fraxini 2 (AVF2) as Intravesical Instillation in Patients With Superficial Bladder Cancer According to ICH/GCP (International Conference on Harmonisation/Good Clinical Practice) - Guidelines: a Phase Ib/IIa Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abnoba Gmbh</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abnoba Gmbh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this phase Ib/IIa study is to investigate the maximum tolerable concentration of&#xD;
      abnobaVISCUM速 Fraxini for intravesical instillation in patients with superficial bladder&#xD;
      cancer. Secondary objectives are the local and systemic tolerability, the influence on tumor&#xD;
      remission and the influence on the one-year recurrence rate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A dose-escalation-study according ICH/GCP (International Conference on Harmonisation/Good&#xD;
      Clinical Practice) with different concentrations of abnobaVISCUM速 Fraxini is conducted in two&#xD;
      hospitals in Germany and Egypt. Patients with superficial bladder cancer TaG1/G2 or T1G1/G2&#xD;
      are enclosed after TUR-B (transurethral resection bladder). The tolerability of the different&#xD;
      concentrations is assessed after weekly instillations into the urinary bladder for 6 weeks. A&#xD;
      direct antitumoral effect is assessed on a single marker tumor left in the bladder after a&#xD;
      complete TUR of all other lesions according a study design established by the&#xD;
      EORTC-GENITO-URINARY GROUP (European Organisation for Research and Treatment of Cancer). A&#xD;
      re-TUR is conducted after 12 weeks. Tumor response is measured by biopsy of the marker lesion&#xD;
      and by cytology. Safety of the instillations is measured by analysis of adverse events, vital&#xD;
      signs and clinical laboratory tests. After treatment of a cohort is finished a safety&#xD;
      evaluation is conducted to decide about the increase to the next dosage.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerable concentration of abnobaVISCUM Fraxini for intravesical instillation</measure>
    <time_frame>6 weeks</time_frame>
    <description>The primary objective is to investigate the maximum tolerable concentration of abnobaVISCUM Fraxini for intravesical instillation in patients with superficial bladder cancer. The treatment schedule included 6 weekly instillations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local and systemic tolerability of different concentrations of abnobaVISCUM Fraxini for intravesical instillation</measure>
    <time_frame>6 weeks</time_frame>
    <description>Secondary objectives are to investigate the local and systemic tolerability of different concentrations of abnobaVISCUM Fraxini for intravesical instillation. Main variables of safety analysis are adverse events, vital signs and clinical laboratory tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence on remission and influence on the one year recurrence rate of abnobaVISCUM Fraxini for intravesical instillation</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Secondary objectives are to investigate the influence on remission and influence on the one year recurrence rate measured by histological examination of biopsies of the marker lesion, cytology and cystoscopy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Superficial Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravesical instillation of abnobaVISCUM Fraxini</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abnobaVISCUM Fraxini</intervention_name>
    <description>intravesical instillation 6 times, once weekly, in increasing dosages until dose-limiting-toxicity occurs</description>
    <arm_group_label>Dose escalation</arm_group_label>
    <other_name>viscum album extract</other_name>
    <other_name>mistletoe extract</other_name>
    <other_name>abnobaVISCUM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with clinically proved superficial bladder cancer (Ta G1/G2 or T1G1/G2) 2 - 7&#xD;
             weeks before transurethral resection&#xD;
&#xD;
          -  Written informed consent for study participation and for documentation of disease data&#xD;
             including further distribution of these data&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Muscle invasive bladder carcinoma and/or carcinoma in situ (CIS)&#xD;
&#xD;
          -  Intravesical instillation therapy within 6 months prior to study enrolment&#xD;
&#xD;
          -  Radiotherapy of the bladder prior to study enrolment&#xD;
&#xD;
          -  Contracted bladder (capacity less than 100 ml)&#xD;
&#xD;
          -  Non treated acute or chronic urinary tract infection&#xD;
&#xD;
          -  Allergy against mistletoe extract preparations&#xD;
&#xD;
          -  Subvesical obstructions (e. g. prostate hyperplasia, urethral stenosis, residual urine&#xD;
             volume more than 80 ml)&#xD;
&#xD;
          -  Severe illnesses and circumstances not permitting study participation (e. g.&#xD;
             alcoholism or substance abuse)&#xD;
&#xD;
          -  Pregnancy or lactation (pregnancy test if required) as well as women without&#xD;
             sufficient contraception&#xD;
&#xD;
          -  Participation in another clinical study within 30 days prior to this study&#xD;
&#xD;
          -  Administration of immunotherapeutic and/or cytostatic drugs within 4 weeks prior to&#xD;
             study enrolment&#xD;
&#xD;
          -  Chronic progressive infections (e. g. tuberculosis)&#xD;
&#xD;
          -  Pre-treatment with mistletoe extracts/mistletoe lectins&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Herbert Ruebben, Prof.Dr.Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Director of the Urological Clinic of the University Hospital Essen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Theodor Bilharz Research Institute</name>
      <address>
        <city>Giza</city>
        <zip>12411</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic of Urology of the University Hospital of Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Rose A, El-Leithy T, vom Dorp F, Zakaria A, Eisenhardt A, Tschirdewahn S, R端bben H. Mistletoe Plant Extract in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Phase Ib/IIa Single Group Dose Escalation Study. J Urol. 2015 Oct;194(4):939-43. doi: 10.1016/j.juro.2015.04.073. Epub 2015 Apr 22.</citation>
    <PMID>25910967</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>December 5, 2013</study_first_submitted>
  <study_first_submitted_qc>December 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2013</study_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>superficial bladder cancer</keyword>
  <keyword>mistletoe extract</keyword>
  <keyword>maximum tolerated dose</keyword>
  <keyword>marker tumor</keyword>
  <keyword>remission</keyword>
  <keyword>recurrence rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Viscum album peptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

